Exploring Updates in TiNivo-2 From ESMO 2024

Opinion
Video

Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ESMO 2024, shows potential for improving outcomes in certain cancer treatments.

Recent Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert in this video
2 experts in this video
2 experts in this video
1 expert in this video
Related Content
Blue Light Cystoscopy Associated With Lower Risk of Recurrence of NMIBC

Blue Light Cystoscopy Associated With Lower Risk of Recurrence of NMIBC

Jonah Feldman
March 24th 2025
Article

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.

Read More

EAP Enhances Access to Cretostimogene Grenadenorepvec

EAP Enhances Access to Cretostimogene Grenadenorepvec

Hannah Clarke
March 12th 2025
Article

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the Society of Urologic Oncology.

Read More

Expert Explores Trials in CIS-Refractory Bladder Cancer

Expert Explores Trials in CIS-Refractory Bladder Cancer

Jason M. Hafron, MD, CMO
March 12th 2025
Article

Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.

Read More

Cystectomy-Free Survival Is Detailed With Nadofaragene

Cystectomy-Free Survival Is Detailed With Nadofaragene

Benjamin Saylor
March 10th 2025
Article

Treatment of unresponsive non–muscle-invasive bladder cancer with nadofaragene firadenovec showed a 66% chance of survival and cystectomy-free status at 60 months.

Read More

Moving Beyond BCG in Bladder Cancer

Moving Beyond BCG in Bladder Cancer

Robert L. Ferris, MD, PhD
March 6th 2025
Article

Given different scientific and clinical meeting schedules, considering advances in genitourinary oncology in novel therapies is relevant.

Read More

Roundtable Roundup: Bladder Cancer

Roundtable Roundup: Bladder Cancer

Targeted Oncology Staff
February 21st 2025
Article

In separate, live virtual events, David H. Aggen, MD, PhD; and Matthew R. Zibelman, MD, discussed the case of a patient with urothelial carcinoma and potential treatment options.

Read More